| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $247.5M | +74.5% |
| SG&A Expense | $37.9M | +22.1% |
| Operating Income | -$285.4M | -65.1% |
| Interest Expense | $4.7M | +50.6% |
| Net Income | -$252.1M | -66.1% |
| EPS (Basic) | -$3.75 | -29.8% |
| EPS (Diluted) | -$3.75 | -29.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $340.2M | +45.3% |
| Short-term Investments | $402.8M | +27.6% |
| Current Assets | $770.4M | +37.6% |
| Total Assets | $825.9M | +42.3% |
| Current Liabilities | $39.8M | +107.8% |
| Total Liabilities | $75.8M | +68.5% |
| Stockholders' Equity | $750.1M | +40.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$230.1M | -58.3% |
| Investing Cash Flow | -$109.7M | +50.9% |
| Financing Cash Flow | $445.8M | +26.2% |